看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | -89.2x - -98.5x | -93.9x |
| Selected Fwd EBITDA Multiple | 5.1x - 5.6x | 5.4x |
| Fair Value | ₩47,635 - ₩52,555 | ₩50,095 |
| Upside | 21.7% - 34.2% | 28.0% |
| Benchmarks | Ticker | Full Ticker |
| Oscotec Inc. | A039200 | KOSDAQ:A039200 |
| Komipharm International Co., Ltd. | A041960 | KOSDAQ:A041960 |
| Hanall Biopharma Co., Ltd. | A009420 | KOSE:A009420 |
| ADBiotech Co., Ltd. | A179530 | KOSDAQ:A179530 |
| WooGene B&G Co., Ltd | A018620 | KOSDAQ:A018620 |
| Mezzion Pharma Co.,Ltd. | A140410 | KOSDAQ:A140410 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | ||
| KOSDAQ:A039200 | KOSDAQ:A041960 | KOSE:A009420 | KOSDAQ:A179530 | KOSDAQ:A018620 | KOSDAQ:A140410 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | NM- | -29.9% | NM- | -2.2% | NM- | |
| 3Y CAGR | NM- | NM- | -36.1% | NM- | 18.6% | NM- | |
| Latest Twelve Months | 97.4% | 438.7% | -32.9% | 15.0% | -10.8% | -3.1% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -352.6% | -0.1% | 7.5% | -28.8% | 8.1% | -64.2% | |
| Prior Fiscal Year | -622.1% | -6.4% | 3.7% | -34.7% | 8.1% | -40.8% | |
| Latest Fiscal Year | -2.3% | 15.8% | 2.4% | -27.8% | 7.5% | -154.9% | |
| Latest Twelve Months | -2.3% | 15.8% | 2.4% | -27.8% | 7.5% | -154.9% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 28.28x | 7.36x | 9.81x | 2.57x | 1.29x | 133.28x | |
| EV / LTM EBITDA | -1209.6x | 46.6x | 406.9x | -9.2x | 17.3x | -86.0x | |
| EV / LTM EBIT | -351.8x | 69.9x | 5915.9x | -6.9x | 298.6x | -80.3x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -1209.6x | 17.3x | 406.9x | ||||
| Historical EV / LTM EBITDA | -1353.6x | -70.7x | -16.3x | ||||
| Selected EV / LTM EBITDA | -89.2x | -93.9x | -98.5x | ||||
| (x) LTM EBITDA | (13,342) | (13,342) | (13,342) | ||||
| (=) Implied Enterprise Value | 1,189,530 | 1,252,136 | 1,314,743 | ||||
| (-) Non-shareholder Claims * | 27,004 | 27,004 | 27,004 | ||||
| (=) Equity Value | 1,216,534 | 1,279,141 | 1,341,747 | ||||
| (/) Shares Outstanding | 30.0 | 30.0 | 30.0 | ||||
| Implied Value Range | 40,541.21 | 42,627.59 | 44,713.97 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 40,541.21 | 42,627.59 | 44,713.97 | 39,150.00 | |||
| Upside / (Downside) | 3.6% | 8.9% | 14.2% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | |
| Enterprise Value | 961,777 | 431,638 | 1,363,476 | 28,569 | 71,870 | 1,147,783 | |
| (+) Cash & Short Term Investments | 102,728 | 22,448 | 24,706 | 1,679 | 20,778 | 28,617 | |
| (+) Investments & Other | 2 | 1,010 | 44,134 | 1,923 | 6,082 | 3 | |
| (-) Debt | (13,816) | (43,839) | (1,448) | (11,722) | (31,658) | (1,616) | |
| (-) Other Liabilities | (4,604) | (3,257) | 0 | 1,862 | (41,622) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | (1,796) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1,046,088 | 407,999 | 1,430,869 | 20,515 | 25,450 | 1,174,787 | |
| (/) Shares Outstanding | 38.2 | 69.7 | 50.7 | 11.4 | 28.9 | 30.0 | |
| Implied Stock Price | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |